Skip to content
Screener

Tango Therapeutics TNGX Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$53.8MBeat by $53.3M
EPS$0.13Beat by $0.12
Revenue estimate$556.0K
EPS estimate$0.01

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$0.34

Financials

Q3 2025

Income statement

See full
Revenue$53.8M+364%
Operating income$14.1M+143%
Net income$15.9M+154%
EPS (diluted)$0.13+148%

Balance sheet

See full
Cash & equivalents$60.9M+9.3%
Total debt$34.8M-7.6%
Total equity$160.0M-30.2%
Total assets$210.1M-40.4%

Cash flow

See full
Operating cash flow-$31.0M+7.3%
CapEx$151.0K+31.3%
Free cash flow-$31.1M+7.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$934.59M+12.1%
Enterprise value$908.44M+11.3%
P/S14.1×-5.2×

Profitability

See full
Operating margin-165.9%-54.2pp
Net margin-151.1%-48.2pp
FCF margin-220.7%-40.2pp

Returns & leverage

See full
Return on equity-51.7%+3.2pp
Debt / equity0.2×+0.1×
Current ratio8.9×+0.9×

FAQ

When did Tango Therapeutics report Q3 2025 earnings?
Tango Therapeutics (TNGX) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Tango Therapeutics's Q3 2025 revenue and EPS?
Tango Therapeutics reported revenue of $53.8M and eps of $0.13 for Q3 2025.
Did Tango Therapeutics beat estimates in Q3 2025?
Revenue beat the consensus estimate of $556.0K by $53.3M. EPS beat the consensus estimate of $0.01 by $0.12.
How did Tango Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 363.6% from $11.6M a year earlier.
Where can I find Tango Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-263684) and the 10-Q periodic report (0001193125-25-263680) directly on SEC EDGAR. The filing index links above go to sec.gov.